Dr. Robert Clinton Bast Jr., MD

Dr. Bast practices at The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System.

Dr. Bast's NPI, 1013901008, was assigned on September 6, 2005. Dr. Bast graduated from Harvard Medical School in 1971. Dr. Bast's Texas license number on file is J6871.

Dr. Bast's primary practice is The University of Texas MD Anderson Cancer Center, at 1515 Holcombe Blvd, Houston, TX 77030.

Dr. Bast's primary practice is The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System. The medical group on file is Physicians Referral Service.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Bast practices. Vendor and product names are available with a free account.

Internal medicine is Dr. Bast's primary specialty in the NPI Registry, under taxonomy code 207RH0000X. The record also lists hematology. Dr. Bast is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Bast's licenses on file in 12 states: Texas, Florida, Arizona, Georgia, Oklahoma, Alabama, Louisiana, Massachusetts, Mississippi, North Carolina, Tennessee and Washington.

Dmand AI lists lymphedema among the conditions Dr. Bast treats.

CMS data shows 95 Medicare services from Dr. Bast across 1 procedure code in 2024, all of them office visits, for 63 Medicare patients. Medicare paid $6,015 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 63 Medicare patients who saw Dr. Bast in 2024. The largest group is 65 to 74, with 32 patients. 75% of them have cancer, and 75% have high cholesterol. Their average risk score is 1.42, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Bast's median patient age at 73, with 100% women.

In 2017, Dr. Bast wrote 13 Medicare Part D claims. Every claim was for a generic drug. They cover 1 drug, with $380 in total drug cost. In 2016, CMS named 16 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Bast for performance year 2024, reported as part of a group. Dr. Bast accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 503 papers to Dr. Bast, published from 2003 to 2024. 2019 was the busiest year, with 18. The most frequent topics are Ovarian Neoplasms, Biomarkers, Tumor and Antibodies, Monoclonal. Dr. Bast has published most often in Gynecol Oncol. Dr. Bast's most frequent co-authors are Gordon B. Mills, MD, PhD, Zhen Lu, MD and Karen H. Lu, MD.

Dmand AI lists 4 awards for Dr. Bast, most recently Fellow in 2017. Dr. Bast serves on Expert Panel American Society of Clinical Oncology (ASCO).

Dr. Bast graduated from Harvard Medical School in 1971. Dr. Bast is a member of AACR and ASCO.

Dr. Bast is in network with 4 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Cigna. PPO plans come from the most carriers, 3. Check the plan with the practice before a visit.